New research from the University of Cincinnati promises a treatment to repair the damage caused by stroke. Details are published in the journal Cell Reports.
There are currently no drugs approved to repair the damage caused by a stroke. The study found that an experimental drug called NVG-291-R it allows for repair of the nervous system and significant functional recovery, at least this has been observed in an animal model of severe ischemic stroke.
“We are very excited about the data because they show significant improvement in motor function, sensory function, spatial learning and memory,” he said. Agnes (Yu) LuoPhD, Associate Professor in the Department of Molecular Genetics and Biochemistry at UC School of Medicine and lead author of the study.
Luo said the drug would be a “significant advantage “when the first results are transferred to clinical settings. More studies and validation of results from independent groups are needed to determine if the drug is equally effective in repairing damage from ischemic stroke in human patients.
“Most of the therapies currently being studied primarily focus on reducing the early damage of a stroke,” Luo said. “But our group has focuses on neurorepair as an alternative and has now shown that treatment with NVG-291-R not only provides neuroprotection to reduce neuronal death, but also robust neuroreparative effects.”
The study also found that the drug was effective seven days later of stroke. “The only current drug approved by the FDA to treat stroke does not repair damage and must be administered within 4.5 hours of the onset of the stroke,” Luo said.
“Most of the therapies studied must be applied within 24 to 48 hours of the onset of a stroke. A product that repairs stroke damage even a week after symptoms appear would change the paradigm of stroke treatment.”
Jerry SilverPhD, study co-author and professor of neuroscience at the CWRU School of Medicine, said the study shows the drug repairs damage in at least two ways: by creating new neural connections Y Improving neuron migration newborn stem cells.
“The ability of NVG-291-R to improve plasticity was demonstrated using staining techniques that clearly showed that a Increase in axonal sprouting in the damaged part of the brainsaid Silver. “This improved plasticity is excellent confirmation of the same potent mechanisms that we and other investigators have demonstrated with NVG-291-R in spinal cord injury.”
NervGen Pharma Corp. owns the exclusive worldwide rights to NVG-291 and the drug is also currently being evaluated in a Phase 1 clinical trial in healthy volunteers. NervGen plans to begin safety and efficacy studies in patients with spinal cord injury, Alzheimer’s disease and multiple sclerosis in 2022 and 2023.